Latest Breaking News On - Silverstein foundation for parkinson - Page 1 : vimarsana.com

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson s Disease

BETHESDA, Md., April 24, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule.

Jonas hannestadMatthias alderElio ambrosioNic johnsonSwiss innovation agencyEuropean union horizonExchange commission onCompany annual report on formMichaelj fox foundation for parkinson researchBellberry human research ethics committeeSilverstein foundation for parkinsonExchange commissionGain therapeutics incGain chief medical officer jonasSilverstein foundationSwiss innovation

Gain Therapeutics Announces Positive Results from the

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology.

Jonas hannestadMatthias alderElio ambrosioNic johnsonCompany annual report on formEuropean union horizonSilverstein foundation for parkinsonExchange commission onMichaelj fox foundation for parkinson researchSwiss innovation agencyExchange commissionGain therapeutics incBellberry human research ethics committeeGain chief medical officer jonasSilverstein foundationSwiss innovation

Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jonas hannestadMatthias alderGain therapeutics incSilverstein foundation for parkinsonBellberry human research ethics committeeMichaelj fox foundation for parkinson researchEuropean union horizonSwiss innovation agencyGain therapeuticsGain chief medical officer jonasSilverstein foundationSwiss innovationSite directed enzyme enhancement therapy

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

BETHESDA, Md., April 08, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule.

Elio ambrosioNic johnsonMatthias alderGruntal coExchange commissionEuropean union horizonSwiss innovation agencyGain therapeutics incFordham universityMichaelj fox foundation for parkinson researchExchange commission onMerck coCompany annual report on formSilverstein foundation for parkinsonGene mackGain therapeutics

Gain Therapeutics Bolsters Management Team with the

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology.

Elio ambrosioMatthias alderNic johnsonExchange commission onCompany annual report on formSilverstein foundation for parkinsonEuropean union horizonMichaelj fox foundation for parkinson researchGain therapeutics incGruntal coSwiss innovation agencyExchange commissionFordham universityMerck coGene mackGain therapeutics